X4 Pharmaceuticals (XFOR) Current Leases (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported Current Leases for 8 consecutive years, with $465000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases fell 66.01% year-over-year to $465000.0; the trailing twelve-month figure through Jun 2026 stood at $465000.0 (down 66.01% YoY), and the FY2025 full-year result was $994000.0, down 20.54% from the prior year.
• Current Leases slipped to $465000.0 in Q2 2026 per XFOR's latest filing, from $733000.0 in the prior quarter.
• Across five years, Current Leases topped out at $1.4 million in Q2 2025 and bottomed at $465000.0 in Q2 2026.
• Historically, Current Leases has averaged $1.1 million across 5 years, with a median of $1.2 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Current Leases rose 26.74% in 2022, then slumped 66.01% in 2026.
• Over 5 years, Current Leases stood at $1.2 million in 2022, then retreated by 8.26% to $1.1 million in 2023, then climbed by 13.83% to $1.3 million in 2024, then retreated by 20.54% to $994000.0 in 2025, then plunged by 53.22% to $465000.0 in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $465000.0, $733000.0, and $994000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.